Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Head & Neck 2 Gastrointestinal 2 Endocrine 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma 1

Interventions

Rituximab 1401 Cyclophosphamide 1306 Vincristine 668 Doxorubicin 587 Etoposide 527 Prednisone 511 Cytarabine 486 fludarabine 470 Methotrexate 445 Dexamethasone 413 fludarabine phosphate 400 Lenalidomide 356 Filgrastim 343 Bendamustine Hydrochloride 282 Radiotherapy 267 venetoclax 261 ibrutinib 258 obinutuzumab 236 Peripheral Blood Stem Cell Transplantation 234 Melphalan 230 Granulocyte Colony-Stimulating Factor 215 Bortezomib 204 Gemcitabine 202 Busulfan 188 Whole-Body Irradiation 187 Mycophenolic Acid 175 Tacrolimus 165 Specimen Handling 162 Magnetic Resonance Spectroscopy 155 Calcium Dobesilate 150

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

efatutazone × Lymphoid × Clear all

NCT01504490 2017-02-14

Phase I Study of CS-7017 and Bexarotene

Georgetown University

Phase 1 Terminated

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡